green tick

Medicines update

0 comments Read Later

Medicines update

Combined glucosamine and chondroitin effective for knee pain

The combination of glucosamine and chondroitin sulphate is as effective for treating knee osteoarthritis as taking celecoxib, a new study shows.

The study, published in the Annals of the Rheumatic Disease, found that patients with moderate-to-severe pain that took glucosamine and chondroitin for a six month period experienced a 50.1% decrease in pain, compared to a 50.2% decrease among patients taking celecoxib (Celebrex).

Both groups of patients experienced a significant reduction (of more than 50%) in the presence of joint swelling, with a similar reduction seen for effusion. No differences were observed for secondary outcomes, and adverse events were low and similarly distributed between groups.

The researchers concluded that glucosamine and chondroitin had “comparable efficacy” to celecoxib in reducing pain, stiffness, functional limitation and joint swelling/effusion after six months in patients with painful knee osteoarthritis, with “a good safety profile”.

Nanopatch vaccine receives funding boost

Vaccine technology company Vaxxas has attracted a $25 million investment from venture capital firm OneVentures.

The Nanopatch, invented at the University of Queensland’s Australian Institute for Bioengineering and Nanotechnology, seeks to replace traditional needle and syringe methods with a small patch that delivers vaccines painlessly.

Yet to be clinically proven, the investment will be used to advance a series of clinical programs and develop a pipeline of new vaccine products for major diseases, using the Nanopatch technology.

More information about the Nanopatch investment is available here.

TGA cautions against Dr Ming’s capsules

The TGA has issued a safety advisory warning for Dr Ming’s Chinese capsules, a product containing undeclared amounts of prescription-only sildenafil.

Dr Ming's Chinese capsules have not been assessed by the TGA for quality, safety or efficacy as required under Australian legislation, and the place of manufacture is not approved by the TGA.

TGA investigations have shown that a number of people in Australia may have bought the product online.

Read more about the TGA warning here.


 

 Subscribe to our Newsletter


 Breaking news and special features
 A daily must-read for pharmacists
 Delivered to your inbox
By filling in your email address and clicking submit with this option selected, you agree to receive email communications from us relevant to the healthcare industry. You always have the option of unsubscribing later via an unsubscribe link or your subscriptions management page. View our privacy policy here.

Your profile is
0% complete


 
 

Pharmacy News on Twitter

­

My list
  •  
Read Later